Jin Yang-gon, Chairman of HLB Group, has demonstrated his confidence in the group's future growth by continuously purchasing shares of its key subsidiaries.


HLB Group Chairman Jin Yang-gon Expands Subsidiary Share Purchases, Demonstrates Commitment to Responsible Management View original image

On June 9, HLB Group announced that Chairman Jin recently made additional purchases of shares in major group subsidiaries, including HLB Genex, HLB BioStep, HLB Panagene, HLB Innovation, and HLB Therapeutics.


From June 2 to June 8, Chairman Jin bought 103,735 shares of HLB Genex through four separate market transactions. On June 5 and June 8, he additionally acquired 37,109 shares of HLB Innovation. He also purchased 67,321 shares of HLB Therapeutics in three rounds between June 4 and June 8. On June 8, he continued his series of purchases by acquiring 25,000 shares of HLB BioStep and 14,562 shares of HLB Panagene on the open market.


As a result, Chairman Jin's holdings have increased to 719,430 shares of HLB Genex, 405,373 shares of HLB Panagene, 359,013 shares of HLB Therapeutics, 221,490 shares of HLB Innovation, and 171,706 shares of HLB BioStep. With HLB Group set to announce major new drug approval events and clinical results in the second half of the year, these moves are seen as a demonstration of his trust in the group's long-term growth potential and the business value of each subsidiary, rather than focusing on short-term market fluctuations.


HLB Group is awaiting the U.S. FDA's decision on approval for the combination therapy of rivoceranib and camrelizumab for liver cancer in July, and lirafigratinib as a treatment candidate for cholangiocarcinoma in September. In addition, HLB Therapeutics is scheduled to announce the results of its global Phase 3 (SEER-2) clinical trial for the neurotrophic keratitis (NK) treatment candidate 'RGN-259' in the second half of the year.



An HLB Group official stated, "Chairman Jin's successive subsidiary share purchases demonstrate his conviction in the group's growth potential and corporate value," adding, "We will continue to do our utmost to ensure that the company's value is properly recognized based on the performance of our core pipeline."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing